Tags

Type your tag names separated by a space and hit enter

The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.
J Child Adolesc Psychopharmacol. 2004 Winter; 14(4):593-600.JC

Abstract

OBJECTIVE

The aim of this retrospective chart review was to evaluate the effectiveness and tolerability of aripiprazole for the treatment of children and adolescents with bipolar disorders.

METHODS

The medical charts of all children and adolescents with a DSM-IV diagnosis of bipolar disorder, type I, type II, not otherwise specified (NOS), or schizoaffective disorder, bipolar type, and who were treated with aripiprazole were reviewed by two child and adolescent psychiatrists who independently confirmed their DSM-IV diagnoses, severity, and the improvement of illness using the Clinical Global Impression (CGI) Severity and Improvement scores for bipolar disorder (CGI-BP) and the Clinical Global Assessment Scale (CGAS).

RESULTS

Thirty patients who were treated with aripiprazole were identified (mean starting dose=9 +/- 4 mg/day, mean final dose=10 +/- 3 mg/day). The overall response rate, defined by a CGI-Improvement score of < or = 2 at endpoint, was 67%. There was a statistically significant improvement in CGAS scores (48 +/- 11 to 65 +/- 11, signed rank = 191, p <0.0001) and CGI-S scores (4.2 +/- 0.8 to 2.8 +/- 1.0, signed rank=-172, p <0.0001, effect size=1.90) from baseline to endpoint. No serious adverse events were identified. Common side effects were sedation (n=10, 33%), akathisia (n=7, 23%), and gastrointestinal disturbances (n=2, 7%). Baseline and endpoint weights were available for 14 (47%) of the patients. Change in weight ranged from +5 to -21 kg and 12 (86%) of 14 patients lost weight (mean weight loss was 3 +/- 6 kg).

CONCLUSIONS

This retrospective chart review suggests that aripiprazole may be effective and well tolerated for children and adolescents with bipolar disorders. Controlled studies of aripiprazole for the treatment of pediatric bipolar disorder are necessary.

Authors+Show Affiliations

Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA. drew.barzman@fuse.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15662152

Citation

Barzman, Drew H., et al. "The Effectiveness and Tolerability of Aripiprazole for Pediatric Bipolar Disorders: a Retrospective Chart Review." Journal of Child and Adolescent Psychopharmacology, vol. 14, no. 4, 2004, pp. 593-600.
Barzman DH, DelBello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14(4):593-600.
Barzman, D. H., DelBello, M. P., Kowatch, R. A., Gernert, B., Fleck, D. E., Pathak, S., Rappaport, K., Delgado, S. V., Campbell, P., & Strakowski, S. M. (2004). The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. Journal of Child and Adolescent Psychopharmacology, 14(4), 593-600.
Barzman DH, et al. The Effectiveness and Tolerability of Aripiprazole for Pediatric Bipolar Disorders: a Retrospective Chart Review. J Child Adolesc Psychopharmacol. 2004;14(4):593-600. PubMed PMID: 15662152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. AU - Barzman,Drew H, AU - DelBello,Melissa P, AU - Kowatch,Robert A, AU - Gernert,Beth, AU - Fleck,David E, AU - Pathak,Sanjeev, AU - Rappaport,Katherine, AU - Delgado,Sergio V, AU - Campbell,Pamela, AU - Strakowski,Stephen M, PY - 2005/1/22/pubmed PY - 2005/5/27/medline PY - 2005/1/22/entrez SP - 593 EP - 600 JF - Journal of child and adolescent psychopharmacology JO - J Child Adolesc Psychopharmacol VL - 14 IS - 4 N2 - OBJECTIVE: The aim of this retrospective chart review was to evaluate the effectiveness and tolerability of aripiprazole for the treatment of children and adolescents with bipolar disorders. METHODS: The medical charts of all children and adolescents with a DSM-IV diagnosis of bipolar disorder, type I, type II, not otherwise specified (NOS), or schizoaffective disorder, bipolar type, and who were treated with aripiprazole were reviewed by two child and adolescent psychiatrists who independently confirmed their DSM-IV diagnoses, severity, and the improvement of illness using the Clinical Global Impression (CGI) Severity and Improvement scores for bipolar disorder (CGI-BP) and the Clinical Global Assessment Scale (CGAS). RESULTS: Thirty patients who were treated with aripiprazole were identified (mean starting dose=9 +/- 4 mg/day, mean final dose=10 +/- 3 mg/day). The overall response rate, defined by a CGI-Improvement score of < or = 2 at endpoint, was 67%. There was a statistically significant improvement in CGAS scores (48 +/- 11 to 65 +/- 11, signed rank = 191, p <0.0001) and CGI-S scores (4.2 +/- 0.8 to 2.8 +/- 1.0, signed rank=-172, p <0.0001, effect size=1.90) from baseline to endpoint. No serious adverse events were identified. Common side effects were sedation (n=10, 33%), akathisia (n=7, 23%), and gastrointestinal disturbances (n=2, 7%). Baseline and endpoint weights were available for 14 (47%) of the patients. Change in weight ranged from +5 to -21 kg and 12 (86%) of 14 patients lost weight (mean weight loss was 3 +/- 6 kg). CONCLUSIONS: This retrospective chart review suggests that aripiprazole may be effective and well tolerated for children and adolescents with bipolar disorders. Controlled studies of aripiprazole for the treatment of pediatric bipolar disorder are necessary. SN - 1044-5463 UR - https://www.unboundmedicine.com/medline/citation/15662152/The_effectiveness_and_tolerability_of_aripiprazole_for_pediatric_bipolar_disorders:_a_retrospective_chart_review_ L2 - https://www.liebertpub.com/doi/full/10.1089/cap.2004.14.593?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -